MEX:RXRX (USA)
Â
Class A
MXN
59.39
+4.39 (+7.98%)
Aug 25
Business Description
Recursion Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US75629V1044
Share Class Description:
MEX:RXRX: Class ATotal Employee Number:
600Description
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 8.19 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.15 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 0.3 | |||||
Beneish M-Score | -4.98 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -9.8 | |||||
3-Year EBITDA Growth Rate | 1.2 | |||||
3-Year EPS without NRI Growth Rate | -1.9 | |||||
3-Year FCF Growth Rate | -7.3 | |||||
3-Year Book Growth Rate | -5.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 18.23 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 84.61 | |||||
9-Day RSI | 73.21 | |||||
14-Day RSI | 64.38 | |||||
6-1 Month Momentum % | -16.68 | |||||
12-1 Month Momentum % | -46.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.03 | |||||
Quick Ratio | 5.03 | |||||
Cash Ratio | 4.55 | |||||
Days Payable | 116.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -40.4 | |||||
Shareholder Yield % | -19.1 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 1.85 | |||||
Operating Margin % | -1008.58 | |||||
Net Margin % | -962 | |||||
EBITDA Margin % | -822.47 | |||||
FCF Margin % | -654.86 | |||||
OCF Margin % | -647.94 | |||||
ROE % | -51.51 | |||||
ROA % | -38.56 | |||||
ROIC % | -72.6 | |||||
3-Year ROIIC % | -74.81 | |||||
ROC (Joel Greenblatt) % | -307.51 | |||||
ROCE % | -43.41 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 33.86 | |||||
PB Ratio | 2.08 | |||||
Price-to-Tangible-Book | 4.04 | |||||
EV-to-EBIT | -2.77 | |||||
EV-to-EBITDA | -3.26 | |||||
EV-to-Revenue | 26.81 | |||||
EV-to-FCF | -4.08 | |||||
Price-to-GF-Value | 1.18 | |||||
| Price-to-Net-Current-Asset-Value | 6.24 | |||||
| Price-to-Net-Cash | 7.73 | |||||
Earnings Yield (Greenblatt) % | -36.1 | |||||
FCF Yield % | -18.4 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Recursion Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 969.79 | ||
| EPS (TTM) (MXN) | -18.701 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 62.75 | ||
| 14-Day RSI | 64.38 | ||
| 14-Day ATR (MXN) | 1.298786 | ||
| 20-Day SMA (MXN) | 54.12 | ||
| 12-1 Month Momentum % | -46.46 | ||
| 52-Week Range (MXN) | 49 - 121.5 | ||
| Shares Outstanding (Mil) | 534.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Recursion Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Recursion Pharmaceuticals Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-25 08:00 | In 184 days | ||
| Annual report for 2026 | 2027-02-25 | In 183 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-25 | In 183 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 08:00 | In 72 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 71 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-15 08:30 | In 21 days | ||
| Guidance call for 2026 | 2026-08-11 10:00 | 54.89 (+0.00%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 08:00 | 55.78 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 55.78 (+0.00%) | ||
| General meeting for 2026 | 2026-06-18 12:00 | 55.46 (-0.14%) |
Show
Entries
Recursion Pharmaceuticals Inc Frequently Asked Questions
What is Recursion Pharmaceuticals Inc(MEX:RXRX)'s stock price today?
The current price of MEX:RXRX is MXN59.39. The 52 week high of MEX:RXRX is MXN121.50 and 52 week low is MXN49.00.
When is next earnings date of Recursion Pharmaceuticals Inc(MEX:RXRX)?
The next earnings date of Recursion Pharmaceuticals Inc(MEX:RXRX) is 2026-11-05 Est..
Does Recursion Pharmaceuticals Inc(MEX:RXRX) pay dividends? If so, how much?
Recursion Pharmaceuticals Inc(MEX:RXRX) does not pay dividend.
Press Release
Articles on Recursion Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers